Journal of Microbiology and Biotechnology
The Korean Society for Microbiology and Biotechnology publishes the Journal of Microbiology and Biotechnology.

2018 ; Vol.28-3: 367~374

AuthorYoung Woong Lee, Young Eun Hwang, Ju Young Lee, Jung-Hoon Sohn, Bong Hyun Sung, Sun Chang Kim
Place of dutyDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea
TitleVEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide
PublicationInfo J. Microbiol. Biotechnol.2018 ; Vol.28-3
AbstractRNA interference provides an effective tool for developing antitumor therapies. Cellpenetrating peptides (CPPs) are delivery vectors widely used to efficiently transport smallinterfering RNA (siRNA) to intracellular targets. In this study, we investigated the efficacy of the cancer-specific CPP carrier BR2 to specifically transport siRNA to cancer-target cells. Our results showed that BR2 formed a complex with anti-vascular endothelial growth factor siRNA (siVEGF) that exhibited the appropriate size and surface charge for in vivo treatment. Additionally, the BR2-VEGF siRNA complex exhibited significant serum stability and high levels of gene-silencing effects in vitro. Moreover, the transfection efficiency of the complex into a cancer cell line was higher than that observed in non-cancer cell lines, resulting in downregulated intracellular VEGF levels in HeLa cells and comprehensively improved antitumor efficacy in the absence of significant toxicity. These results indicated that BR2 has significant potential for the safe, efficient, and specific delivery of siRNA for diverse applications.
Full-Text
Key_wordRNA interference, small-interfering RNA, cell-penetrating peptide, cancer-specific peptide
References
  1. Hannon GJ. 2002. RNA interference. Nature 418: 244-251.
    Pubmed CrossRef
  2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
    Pubmed CrossRef
  3. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
    Pubmed CrossRef
  4. Morris KV, Chan SW, Jacobsen SE, Looney DJ. 2004. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305: 1289-1292.
    Pubmed CrossRef
  5. Aagaard L, Rossi JJ. 2007. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59: 75-86.
    Pubmed CrossRef Pubmed Central
  6. Castanotto D, Rossi JJ. 2009. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
    Pubmed CrossRef Pubmed Central
  7. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. 2007. Interfering with disease: a progress report on siRNAbased therapeutics. Nat. Rev. Drug Discov. 6: 443-453.
    Pubmed CrossRef
  8. Stevenson M, Ramos-Perez V, Singh S, Soliman M, Preece JA, Briggs SS, et al. 2008. Delivery of siRNA mediated by histidine-containing reducible polycations. J. Control. Release 130: 46-56.
    Pubmed CrossRef
  9. Meade BR, Dowdy SF. 2007. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59: 134-140.
    Pubmed CrossRef
  10. Tomar RS, Matta H, Chaudhary PM. 2003. Use of adenoassociated viral vector for delivery of small interfering RNA. Oncogene 22: 5712-5715.
    Pubmed CrossRef
  11. Barquinero J, Eixarch H, Perez-Melgosa M. 2004. Retroviral vectors: new applications for an old tool. Gene Ther. 11 Suppl 1: S3-S9.
    Pubmed CrossRef
  12. Devroe E, Silver PA. 2002. Retrovirus-delivered siRNA. BMC Biotechnol. 2: 15.
    Pubmed CrossRef Pubmed Central
  13. Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L, et al. 2007. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther. 14: 752-759.
    Pubmed CrossRef
  14. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. 2006. RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
    Pubmed CrossRef
  15. de Martimprey H, Bertrand JR, Fusco A, Santoro M, Couvreur P, Vauthier C, et al. 2008. siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36: e2.
    Pubmed CrossRef Pubmed Central
  16. Choi YS, Lee JY, Suh JS, Kwon YM, Lee SJ, Chung JK, et al. 2010. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 31:1429-1443.
    Pubmed CrossRef
  17. Pan R, Xu W, Ding Y, Lu S, Chen P. 2016. Uptake mechanism and direct translocation of a new CPP for siRNA delivery. Mol. Pharm. 13: 1366-1374.
    Pubmed CrossRef
  18. Wang F, Wang Y, Zhang X, Zhang W, Guo S, Jin F. 2014. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J. Control. Release 174: 126-136.
    Pubmed CrossRef
  19. Cleal K, He L, Watson PD, Jones AT. 2013. Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles. Curr. Pharm. Des. 19: 2878-2894.
    Pubmed CrossRef
  20. Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, et al. 2004. Cellular uptake of arginine-rich peptides:roles for macropinocytosis and actin rearrangement. Mol. Ther. 10: 1011-1022.
    Pubmed CrossRef
  21. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. 2003. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278: 585-590.
    Pubmed CrossRef
  22. Milletti F. 2012. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 17: 850-860.
    Pubmed CrossRef
  23. Nakase I, Tanaka G, Futaki S. 2013. Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells. Mol. Biosyst. 9: 855-861.
    Pubmed CrossRef
  24. Vives E, Schmidt J, Pelegrin A. 2008. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta 1786: 126-138.
    CrossRef
  25. Chung JY, Ul Ain Q, Lee HL, Kim SM, Kim YH. 2017. Enhanced systemic anti-angiogenic siVEGF delivery using PEGylated oligo-D-arginine. Mol. Pharm. 14: 3059-3068.
    Pubmed CrossRef
  26. Kanazawa T, Sugawara K, Tanaka K, Horiuchi S, Takashima Y, Okada H. 2012. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptidemodified MPEG-PCL nanomicelles. Eur. J. Pharm. Biopharm. 81: 470-477.
    Pubmed CrossRef
  27. Egorova A, Shubina A, Sokolov D, Selkov S, Baranov V, Kiselev A. 2016. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. Int. J. Pharm. 515:431-440.
    Pubmed CrossRef
  28. Raucher D, Ryu JS. 2015. Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol. Med. 21: 560-570.
    Pubmed CrossRef
  29. Lim KJ, Sung BH, Shin JR, Lee YW, Kim DJ, Yang KS, et al. 2013. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One 8: e66084.
    Pubmed CrossRef Pubmed Central
  30. Wallbrecher R, Ackels T, Olea RA, Klein MJ, Caillon L, Schiller J, et al. 2017. Membrane permeation of arginine-rich cell-penetrating peptides independent of transmembrane potential as a function of lipid composition and membrane fluidity. J. Control. Release 256: 68-78.
    Pubmed CrossRef
  31. Yoo J, Lee D, Gujrati V, Rejinold NS, Lekshmi KM, Uthaman S, et al. 2017. Bioreducible branched poly(modified nona-arginine) cell-penetrating peptide as a novel gene delivery platform. J. Control. Release 246: 142-154.
    Pubmed CrossRef
  32. Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalek J. 2010. Magnetic nanoparticles and targeted drug delivering. Pharmacol. Res. 62: 144-149.
    Pubmed CrossRef
  33. Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, et al. 2009. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther. 17: 95-103.
    Pubmed CrossRef Pubmed Central
  34. Garzon R, Marcucci G, Croce CM. 2010. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9: 775-789.
    Pubmed CrossRef Pubmed Central
  35. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. 2004. Sizedependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377:159-169.
    Pubmed CrossRef Pubmed Central
  36. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. 2009. Sizedependent endocytosis of nanoparticles. Adv. Mater. 21: 419-424.
    Pubmed CrossRef Pubmed Central
  37. Maeda H. 2010. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21: 797-802.
    Pubmed CrossRef
  38. Lee M, Rentz J, Han SO, Bull DA, Kim SW. 2003. Watersoluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther. 10: 585-593.
    Pubmed CrossRef
  39. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. 2005. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol. Ther. 11: 990-995.
    Pubmed CrossRef
  40. Svensen N, Walton JG, Bradley M. 2012. Peptides for cellselective drug delivery. Trends Pharmacol. Sci. 33: 186-192.
    Pubmed CrossRef



Copyright © 2009 by the Korean Society for Microbiology and Biotechnology.
All right reserved. Mail to jmb@jmb.or.kr
Online ISSN: 1738-8872    Print ISSN: 1017-7825    Powered by INFOrang.co., Ltd